ライフサイエンスコーパス: SDD

1 SDD administration significantly downregulated PAR2, IL-

2 SDD and next-day discharge cohorts had similar rates of

3 SDD was more frequently used among male and younger pati

4 SDD was well tolerated, with a low incidence of disconti

5 SDD-40 used as an adjunct to SRP resulted in significant

6 ose flurbiprofen (LDF) alone, 50 mg q.d.; 2) SDD (20 mg b.i.d.) alone; or 3) a combination of SDD plu

7 based catalysts are determined at the M06-2X/SDD|6-311+G(2df,p)//M06-L/SDD|6-31G(d)|MIDI!

8 In addition, SDD treatment was accompanied by lower rates of alveolar

9 Adjunctive SDD-40 provided significantly greater clinical benefits

10 In addition, adjunctive SDD is more effective than a placebo in preventing furth

11 and randomized to receive either adjunctive SDD or placebo for 9 months.

12 te sites (baseline PD 4 to 6 mm), adjunctive SDD-40 provided significant clinical benefits compared t

13 conducted to test the efficacy of adjunctive SDD-40 in 266 subjects with periodontitis.

14 Subgingival debridement plus adjunctive SDD reduced deep pockets (> or =7 mm at baseline) by an

15 subsets of the study population, adjunctive SDD significantly reduced serum biomarkers of bone resor

16 D were greater following SRP with adjunctive SDD than SRP with placebo, achieving statistical signifi

17 th 9 was significantly lower with adjunctive SDD than with adjunctive placebo (P<0.05).

18 D were significantly greater with adjunctive SDD than with adjunctive placebo at 3, 6, and 9 months (

19 al debridement with a host-modulating agent, SDD, provides clinically and statistically significant b

20 Among those with early and intermediate AMD, SDD prevalence was 49% and 79%, respectively.

21 scribe a framework for the development of an SDD program.

22 se in GCF, with much less MMP-1 and -13, and SDD reduced the odds of elevated MMP-8 by 60% compared t

23 bitory process is either lost or masked, and SDD facilitation predominates at nondepressed synapses.

24 ne group: ligature-induced periodontitis and SDD treatment.

25 vulnerable to progressive periodontitis, and SDD may modify that risk.

26 outer segments and RPE apical processes and SDD in eyes with AMD, slower dark adaptation might be re

27 mortality was 25.4% and 24.1% during SOD and SDD, respectively (adjusted odds ratio, 0.96 [95% CI, 0.

28 5.9% and 4.6% of the patients during SOD and SDD, respectively (odds ratio, 0.77 [95% CI, 0.65-0.91];

29 in the clinical outcome analysis for SOD and SDD, respectively.

30 The ULD and SDD mediate a critical interaction with IkappaBalpha tha

31 acute appendicitis undergoing appendectomy, SDD is not associated with an increase in 30-day hospita

32 (M06/SDD-6-311G(d,p)-IEFPCM(acetone)//B3LYP/SDD-6-31G(d)) predict that the product distribution is c

33 DFT (B3LYP-D/Def2-QZVP//B3LYP/SDD:6-31+G(d)) predicts that the alkylation mechanism fo

34 interest overlying and in 5 located between SDD or conventional drusen with the same retinal eccentr

35 genase activity was significantly reduced by SDD treatment relative to placebo based on intent-to-tre

36 of validating and implementing new cefepime SDD criteria, we evaluated the performances of Vitek 2,

37 ethods (selective digestive decontamination [SDD], acidification of gastric content, early enteral fe

38 r = 1 microg/ml; susceptible dose dependent (SDD), 2 microg/ml; and resistant (R), > or = 4 microg/ml

39 /ml (>or=17 mm); susceptible dose dependent (SDD), MIC of 2 microg/ml (14 to 16 mm); and resistant (R

40 codified in new susceptible dose-dependent (SDD) breakpoints promulgated by the Clinical and Laborat

41 ptic facilitation [spike duration-dependent (SDD) facilitation], particularly at nondepressed synapse

42 to 32 microg/ml (susceptible dose-dependent [SDD]), or >/=64 microg/ml (resistant) and 10 isolates wi

43 19 eyes with subretinal drusenoid deposits (SDD) vs 47 eyes without SDD, rod-mediated dark adaptatio

44 h and without subretinal drusenoid deposits (SDD), using swept-source optical coherence tomography (S

45 n juvenile Aplysia: homosynaptic depression, SDD facilitation, and SDI facilitation.

46 We now describe SDD effects on biomarkers of collagen degradation and bo

47 11.58 keV, a silicon drift chamber detector (SDD) detector, and pure element reference standards.

48 h a high-performance silicon drift detector (SDD) and two-dimensional/three-dimensional (2D/3D) scann

49 ults have suggested that same-day discharge (SDD) after appendectomy is safe and does not result in h

50 monstrated safety of the same-day discharge (SDD) after percutaneous coronary intervention (PCI), upt

51 egarding the outcomes of same-day discharge (SDD) PCI and to describe a framework for the development

52 hesized that social developmental disorders (SDD) like autism, Asperger's disorder and the social-emo

53 oach termed subtracted differential display (SDD) to identify genes whose expression is regulated by

54 d a C-terminal scaffold/dimerization domain (SDD).

55 alpha-helical scaffold/dimerization domain (SDD).

56 Subantimicrobial dose doxycycline (SDD) has been used as an adjunct in periodontal treatmen

57 safety of subantimicrobial dose doxycycline (SDD) in 128 postmenopausal osteopenic females with moder

58 hown that subantimicrobial dose doxycycline (SDD) is of clinical benefit in the treatment of chronic

59 a 2-year subantimicrobial-dose doxycycline (SDD) regimen (double-masked, placebo-controlled clinical

60 us study, subantimicrobial dose doxycycline (SDD) significantly improved clinical parameters associat

61 rted that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomark

62 ration of subantimicrobial dose doxycycline (SDD) to chronic periodontitis (CP) patients has repeated

63 djunctive subantimicrobial dose doxycycline (SDD) with scaling and root planing leads to improved cli

64 ment with subantimicrobial dose doxycycline (SDD), 20 mg bid, exerted an antimicrobial effect on the

65 egimen of subantimicrobial dose doxycycline (SDD; 20 mg twice a day) was evaluated in postmenopausal

66 trial of subantimicrobial dose doxycycline (SDD; 20 mg two times a day).

67 djunctive subantimicrobial dose doxycycline (SDD; 20 mg, twice daily) provides significant clinical b

68 ated that subantimicrobial-dose-doxycycline (SDD) treatment of post-menopausal osteopenic women signi

69 DD formulation containing 40 mg doxycycline (SDD-40) to be taken once daily has been developed.

70 and safety of subantimicrobial doxycycline (SDD) in 128 postmenopausal osteopenic women with moderat

71 of adjunctive subantimicrobial doxycycline (SDD) or placebo.

72 ination) of these two host-modulating drugs (SDD plus low-dose NSAID) to CP patients, on selected neu

73 creased 7% per month (95% CI, 1%-13%) during SDD (P = .02) and 4% per month (95% CI, 0%-8%) during SO

74 evalence was 5.6% (95% CI, 4.6%-6.7%) during SDD and 11.8% (95% CI, 10.3%-13.2%) during SOD (P < .001

75 TP showed a similar pattern of change during SDD treatment, and GCF collagenase activity and ICTP wer

76 rianal swabs were significantly lower during SDD compared with SOD; for aminoglycoside resistance, av

77 One group of eight SDD subjects performed normally on all tests of face per

78 e units were randomized to administer either SDD or SOD.

79 visit and were randomized to receive either SDD 20 mg bid or placebo bid for 9 months.

80 Criteria for SDD presence were identification on >/=1 en face modalit

81 icrog/ml doxycycline plates at 24 months for SDD versus placebo, the percentage that was clinically r

82 By using CFP only for SDD detection per the AREDS protocol, prevalence of SDD

83 GCF was collected from SDD- and placebo-treated PM subjects (n=64 each) at the

84 did not differ between the treatment groups (SDD: 79% to 76%; placebo: 83% to 70%; P = 0.2).

85 Of the 20 981 patients, 4662 (22.2%) had SDD and 16319 (77.8%) were discharged within 1 or 2 days

86 One impaired SDD subgroup had poor perception of facial structure but

87 t.We conclude that the social disturbance in SDD does not invariably lead to impaired face recognitio

88 to 2013, there has been a modest increase in SDD after PCI.

89 < .001; I(2) = 33%) in trials investigating SDD with systemic antimicrobial therapy and 1.00 (.84-1.

90 ined at the M06-2X/SDD|6-311+G(2df,p)//M06-L/SDD|6-31G(d)|MIDI!

91 pike with 4-aminopyridine induces adult-like SDD synaptic facilitation.

92 Density functional theory calculations (M06/SDD-6-311G(d,p)-IEFPCM(acetone)//B3LYP/SDD-6-31G(d)) pre

93 In deep sites (baseline PD > or =7 mm), SDD-40 provided significant benefits over control for me

94 breakpoints are as follows: S, > or = 17 mm; SDD, 14 to 16 mm; and R, < or = 13 mm.

95 Among placebo (but not SDD) participants, RCAL changes were associated with con

96 Among placebo (but not SDD) participants, relative CAL changes were associated

97 Greater adoption of SDD programs after PCI has the potential to improve pati

98 Unit-wide application of SDD and SOD was associated with low levels of antibiotic

99 Although the benefits of SDD therapy, such as improvement in the parameters of pe

100 (20 mg b.i.d.) alone; or 3) a combination of SDD plus LDF (combination).

101 stics play critical role in determination of SDD after PCI.

102 animal-model study evaluated the effects of SDD monotherapy on the expressions of the following key

103 study was conducted to test the efficacy of SDD (20 mg doxycycline B.I.D.) in combination with SRP i

104 his study was to investigate the efficacy of SDD-40 when used as an adjunct to SRP for the treatment

105 mportant to the successful implementation of SDD after PCI.

106 To evaluate the influence of SDD on 30-day readmission rates following appendectomy f

107 comparing 12 months of SOD with 12 months of SDD in 16 Dutch ICUs between August 1, 2009, and Februar

108 red patients had significantly lower odds of SDD along with higher incidence of unplanned readmission

109 In addition, we evaluated the predictors of SDD (compared with next-day discharge) and the causes of

110 tral-domain OCT (to evaluate the presence of SDD).

111 The prevalence of SDD is strongly associated with AMD presence and severit

112 ection per the AREDS protocol, prevalence of SDD was 2% (12/610).

113 Prevalence of SDD was 23% in subjects without AMD and 52% in subjects

114 Overall prevalence of SDD was 32% (197/611), with 62% (122/197) affected in bo

115 lagenase and anti-inflammatory properties of SDD and not to an antimicrobial effect.

116 ere was modest increase in the proportion of SDD after PCI from 2.5% in 2009 to 7.4% in 2013 (P-trend

117 this study was to further assess the role of SDD as an adjunct to scaling and root planing (SRP) in t

118 he available evidence supports the safety of SDD in selected patients after PCI.

119 ulticenter study, the efficacy and safety of SDD were evaluated in conjunction with scaling and root

120 ns for genetic and rehabilitative studies of SDD.

121 The adjunctive use of SDD with SRP is more effective than SRP alone and may re

122 trends and variations in the utilization of SDD after PCI during the contemporary era.

123 I volume hospitals had higher utilization of SDD compared with their respective counterparts.

124 famous faces in 24 adults with a variety of SDD diagnoses.

125 Consensus on SDD detection methods is recommended to advance our know

126 of PubMed was performed for human studies on SDD PCI published in English from January 1, 1995, to Ju

127 In subgroup analysis, only SDD significantly decreased mortality compared with cont

128 Overall, SDD subgroup membership by face recognition did not corr

129 Reduced visibility of cones overlying SDD in the AO images can be because of several possible

130 Using the M06/6-311+G(d,p)-SDD method, various concerted transition states for the

131 ognition did not correlate with a particular SDD diagnosis or subjective ratings of social impairment

132 es (n = 118 subjects), 94 (50.5%) presenting SDD.

133 ith periodontitis were randomized to receive SDD 10 mg qd, 20 mg qd, 20 mg bid, or placebo.

134 study 3, patients were randomized to receive SDD 20 mg bid or placebo.

135 osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunc

136 ere entered and randomly assigned to receive SDD or placebo.

137 ere treated by SRP and randomized to receive SDD-40 or placebo for 9 months with evaluations at 3, 6,

138 with chronic periodontitis randomly received SDD or placebo tablets daily for 2 years adjunctive to p

139 More recently, SDD adjunctive to repeated mechanical debridement result

140 e findings reveal new perspectives regarding SDD efficacy because it can be partially related to proi

141 A modified-release SDD formulation containing 40 mg doxycycline (SDD-40) to

142 The sensitivity of SS-OCT in RPD/SDD detection was 83%, and when using conventional imagi

143 The difference in RPD/SDD detection with either image modality was not statist

144 When using SS-OCT imaging alone, 10% of RPD/SDD cases would be missed, and when using conventional i

145 using conventional imaging alone, 14% of RPD/SDD cases would be missed.

146 The presence of RPD/SDD was confirmed retrospectively in 48 of 52 cases once

147 We show here that the presence of sequence SDD, a characteristic of motif C of segmented NS RNA vir

148 e L mutant, in which the conserved signature SDD motif was replaced by the amino acid residues GNN, e

149 Compared with SOD, SDD was associated with lower rectal carriage of antibio

150 Abnormal face recognition in some SDD subjects is related to impaired perception of facial

151 Ten SDD isolates showed mean ergosterol reductions of 38, 57

152 Our four studies assessed whether long-term SDD changes antibiotic susceptibility of the oral microf

153 Long-term SDD does not contribute to changes in antibiotic suscept

154 pport the therapeutic potential of long-term SDD therapy to reduce periodontal collagen breakdown and

155 We now hypothesize that SDD may also improve biomarkers of bone loss systemicall

156 The SDD mediates IKKbeta dimerization, but dimerization per

157 ve disease (e.g., rheumatoid arthritis), the SDD and NSAID combination therapy synergistically suppre

158 ty was 8964 +/- 2793 cones/mm(2) between the SDD and 863 +/- 388 cones/mm(2) over the SDD, a 90.4% nu

159 atment differences were detected between the SDD and placebo treatments in either the SRP or non-SRP

160 is the reason for the disparity; and can the SDD model explain Bcd gradient formation within the expe

161 or = 3 mm was seen in 15.4% of sites in the SDD group compared to 10.6% of sites in the placebo grou

162 holds of change in PD, 42.9% of sites in the SDD group compared to 31.1% of sites in the placebo grou

163 = 2 mm (P < 0.01), and 15.4% of sites in the SDD group compared to 9.1% of sites in the placebo group

164 At month 9, 42.3% of sites in the SDD group demonstrated CAL gain > or = 2 mm compared to

165 only 2 pockets deepened by > or =4 mm in the SDD group versus 10 in the placebo group.

166 The spirochetal proportions present in the SDD group were significantly lower (P<0.05) than the pai

167 In the SDD group, nearly 40% of 237 pockets > or =7 mm were red

168 MIC > or = 16 microg/ml) for patients in the SDD group.

169 clinically and statistically greater in the SDD group.

170 (PD) > or =6 mm, 72% to 76% of sites in the SDD-40 group demonstrated clinically significant PD redu

171 roup (P <0.0001); 48% to 52% of sites in the SDD-40 group demonstrated PD reductions and CAL gains >

172 8; P = 0.0001) in the placebo group, not the SDD group, and a loss of bone height (OR = 1.38; P = 0.0

173 We also performed a cluster analysis of the SDD patients.

174 rGbeta1 is one of the SDD products that encodes a rat G-protein beta subunit.

175 ot form these structures but are part of the SDD.

176 the SDD and 863 +/- 388 cones/mm(2) over the SDD, a 90.4% numerical reduction.

177 gradient properties are compatible with the SDD model in which Bcd is synthesized at the anterior po

178 Subjects were randomized to SDD (n = 64) or a placebo (n = 64).

179 tive decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination (SOD) a

180 band as seen by SD-OCT were associated with SDD but not conventional drusen.

181 was also significantly reduced in eyes with SDD (ss = -0.003, P = .007).

182 evealed that, controlling for age, eyes with SDD presented a statistically thinner mean CT (ss = -21.

183 ound complication rate between patients with SDD and those discharged 1 or 2 days after surgery (aOR

184 in the odds of readmission for patients with SDD compared with those discharged within 2 days (adjust

185 Of persons with SDD detected by SD OCT and confirmed by at least 1 en fa

186 Persons with SDD were older than those without SDD (70.6 vs. 68.7 yea

187 Short-term therapy with SDD alone produced a significant reduction and LDF alone

188 After age adjustment, those with SDD were 3.4 times more likely to have AMD than those wi

189 flora was detected following treatment with SDD for 24 months, relative to baseline or to placebo.

190 drusenoid deposits (SDD) vs 47 eyes without SDD, rod-mediated dark adaptation time was longer (mean

191 rsons with SDD were older than those without SDD (70.6 vs. 68.7 years, P = 0.0002).

192 s more likely to have AMD than those without SDD (95% confidence interval, 2.3-4.9).